JO3654B1 - مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) - Google Patents

مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)

Info

Publication number
JO3654B1
JO3654B1 JOP/2016/0085A JOP20160085A JO3654B1 JO 3654 B1 JO3654 B1 JO 3654B1 JO P20160085 A JOP20160085 A JO P20160085A JO 3654 B1 JO3654 B1 JO 3654B1
Authority
JO
Jordan
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
compounds
formula
Prior art date
Application number
JOP/2016/0085A
Other languages
English (en)
Inventor
M Savall Bradley
Wu Dongpei
M Swanson Devin
Patrick Lebold Terry
K Ameriks Michael
G B Berry Cynthia
Loic Jourdan Fabrice
Angel Pena Pi??N Miguel
Chen Gang
Ravula Suchitra
Wei LIN David
Zhang Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3654B1 publication Critical patent/JO3654B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتوفر بهذا الاختراع مركبات بالصيغة (I) وأملاحها المقبولة صيدلانيًا أو أكاسيدها النيتروجينية أو تذاوباتها، (I) يتوفر بهذا الاختراع أيضًا مركبات صيدلانية تتضمن مركبات بالصيغة (I) وطرق استخدام مركبات بالصيغة (I).
JOP/2016/0085A 2015-04-29 2016-04-28 مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) JO3654B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
JO3654B1 true JO3654B1 (ar) 2020-08-27

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0085A JO3654B1 (ar) 2015-04-29 2016-04-28 مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)

Country Status (39)

Country Link
US (4) US11312712B2 (ar)
EP (3) EP3901153A1 (ar)
JP (2) JP6800886B2 (ar)
KR (2) KR20170140382A (ar)
CN (1) CN107835814B (ar)
AR (1) AR104447A1 (ar)
AU (2) AU2016255434C1 (ar)
BR (2) BR112017023147B1 (ar)
CA (1) CA2983826A1 (ar)
CO (1) CO2017011017A2 (ar)
CR (1) CR20170484A (ar)
CY (1) CY1124059T1 (ar)
DK (1) DK3288940T5 (ar)
EA (1) EA033281B1 (ar)
EC (1) ECSP17074645A (ar)
ES (1) ES2865330T3 (ar)
GT (1) GT201700231A (ar)
HK (1) HK1252249A1 (ar)
HR (1) HRP20210403T1 (ar)
HU (1) HUE053943T2 (ar)
IL (1) IL254848B (ar)
JO (1) JO3654B1 (ar)
LT (1) LT3288940T (ar)
MA (1) MA41988B1 (ar)
MD (1) MD3288940T2 (ar)
MX (1) MX2017013886A (ar)
MY (1) MY194104A (ar)
NI (1) NI201700129A (ar)
PH (1) PH12017501816A1 (ar)
PL (1) PL3288940T3 (ar)
PT (1) PT3288940T (ar)
RS (1) RS61688B1 (ar)
SG (1) SG11201708190UA (ar)
SI (1) SI3288940T1 (ar)
TW (1) TWI706952B (ar)
UA (1) UA120304C2 (ar)
UY (1) UY36654A (ar)
WO (1) WO2016176460A1 (ar)
ZA (1) ZA201708065B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170141768A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 이미다조피라진 및 피라졸로피리미딘 및 ampa 수용체 조절제로서의 이의 용도
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
ES2971497T3 (es) 2017-10-06 2024-06-05 Takeda Pharmaceuticals Co Compuestos heterocíclicos
JP2022508648A (ja) 2018-10-05 2022-01-19 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
EP3873905A4 (en) * 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
CN117222634A (zh) * 2020-12-16 2023-12-12 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (ar) 1992-11-02 1995-07-11 Pfizer
CA2183084A1 (en) 1994-02-10 1995-08-17 John Eugene Macor 5-heteroarylindole derivatives
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
AU760964B2 (en) 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
EP1309577A2 (en) 2000-08-11 2003-05-14 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CA2576765C (en) * 2004-09-03 2013-05-28 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
EA016286B1 (ru) 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
ATE502675T1 (de) 2006-11-03 2011-04-15 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
WO2009073777A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
US8765784B2 (en) * 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
WO2012020848A1 (en) 2010-08-10 2012-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
WO2014128585A1 (en) 2013-02-19 2014-08-28 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders

Also Published As

Publication number Publication date
MY194104A (en) 2022-11-11
ES2865330T3 (es) 2021-10-15
HK1252249A1 (zh) 2019-05-24
AU2016255434A1 (en) 2017-10-26
HUE053943T2 (hu) 2021-08-30
MA41988A (fr) 2018-07-03
US20210284641A1 (en) 2021-09-16
IL254848A0 (en) 2017-12-31
TW201708217A (zh) 2017-03-01
EP3288940B1 (en) 2021-02-24
JP2018518462A (ja) 2018-07-12
HRP20210403T1 (hr) 2021-10-29
UA120304C2 (uk) 2019-11-11
CN107835814A (zh) 2018-03-23
BR112017023147B1 (pt) 2024-04-30
US20230110576A1 (en) 2023-04-13
AR104447A1 (es) 2017-07-19
PT3288940T (pt) 2021-04-30
MD3288940T2 (ro) 2021-08-31
PH12017501816A1 (en) 2018-04-23
SI3288940T1 (sl) 2021-07-30
GT201700231A (es) 2018-12-20
NZ736057A (en) 2023-08-25
KR20170140382A (ko) 2017-12-20
AU2016255434B2 (en) 2020-05-14
US20180118740A1 (en) 2018-05-03
DK3288940T3 (da) 2021-05-25
PL3288940T3 (pl) 2021-07-12
LT3288940T (lt) 2021-05-10
KR20240017991A (ko) 2024-02-08
US11312712B2 (en) 2022-04-26
BR112017023147A2 (pt) 2018-07-10
IL254848B (en) 2021-01-31
JP7026194B2 (ja) 2022-02-25
CR20170484A (es) 2018-02-26
ZA201708065B (en) 2019-09-25
CY1124059T1 (el) 2022-05-27
EP3288940A1 (en) 2018-03-07
WO2016176460A1 (en) 2016-11-03
JP6800886B2 (ja) 2020-12-16
MA41988B1 (fr) 2021-03-31
MX2017013886A (es) 2018-03-12
JP2021042230A (ja) 2021-03-18
NI201700129A (es) 2019-05-10
SG11201708190UA (en) 2017-11-29
AU2020210231A1 (en) 2020-08-20
EA201792374A1 (ru) 2018-05-31
ECSP17074645A (es) 2018-02-28
TWI706952B (zh) 2020-10-11
EA033281B1 (ru) 2019-09-30
AU2020210231B2 (en) 2021-07-22
DK3288940T5 (da) 2021-09-20
EP3288940B9 (en) 2021-07-21
EP3901153A1 (en) 2021-10-27
AU2016255434C1 (en) 2021-09-23
CO2017011017A2 (es) 2018-03-20
CN107835814B (zh) 2021-07-23
BR122023023802A2 (pt) 2023-12-26
CA2983826A1 (en) 2016-11-03
EP4144736A1 (en) 2023-03-08
US20230114165A1 (en) 2023-04-13
UY36654A (es) 2016-10-31
RS61688B1 (sr) 2021-05-31

Similar Documents

Publication Publication Date Title
JO3654B1 (ar) مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
PH12016501440A1 (en) Novel heterocyclic compounds
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
NZ737399A (en) Ccr2 modulators
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12019501639A1 (en) Jaki selective inhibitors
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
ZA201903291B (en) Fused bicylic pyridine compounds and their use as ampa receptor modulators
TN2017000384A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors.
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
TN2018000175A1 (en) Indane derivatives as mglur7 modulators